Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07035405
PHASE3

Colchicine for Secondary Prevention After Ischemic Stroke (CHANCE-3 EX)

Sponsor: Beijing Tiantan Hospital

View on ClinicalTrials.gov

Summary

The role of colchicine in the secondary prevention of ischemic stroke has not been determinded. This multicenter, randomized, double-blind, placebo-controlled, event-driven clinical trial of CHANCE-3 EX was aimed to assess the efficacy and safety of low-dose colchicine versus placebo on reducing the risk of recurrent ischemic stroke, myocardial infarction and vascular death in patients with minor-to-moderate ischemic stroke.

Official title: Colchicine for Secondary Prevention After Ischemic Stroke (CHANCE-3 EX): a Multicenter, Double-blind, Placebo-controlled, Randomized Clinical Trial

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

7500

Start Date

2025-07-04

Completion Date

2028-12-31

Last Updated

2025-06-27

Healthy Volunteers

No

Conditions

Interventions

DRUG

Colchicine 0.5 mg

Oral colchicine will be initiated with a dose of 0.5 mg per day.

DRUG

Placebo colchicine

Oral placebo colchicine will be initiated with a dose of 0.5 mg per day.